PartitionBio is a UK-based biotech company developing next-generation drug delivery systems using biomolecular condensates formed through liquid-liquid phase separation (LLPS). Their non-viral platform enables efficient delivery of macromolecules like nucleic acids and proteins into human cells, aiming to improve therapeutic outcomes. Backed by the Gates Foundation, PartitionBio is advancing accessible solutions for global health.